The majority of analysts have provided bullish ratings for Karuna Therapeutics, indicating a positive outlook for the stock. The average 12-month price target has also increased by 1.96% over the past month, suggesting that analysts are becoming more optimistic about the company's prospects. This is likely to have a positive impact on the stock price in the short term.